Aravive Inc

NASDAQ:ARAV   3:59:58 PM EDT
5.80
+0.16 (+2.84%)
Products, Other Pre-Announcement

Aravive Inc - Received Guidance From U.S FDA On Phase 3 Trial Design For Avb-500 In Platinum Resistant Ovarian Cancer

Published: 11/19/2020 12:39 GMT
Aravive Inc (ARAV) - Aravive Inc - Received Guidance From U.
S FDA on Phase 3 Trial Design for Avb-500 in Platinum Resistant Ovarian Cancer.
Aravive Inc - Plan to Initiate Avb-500 Phase-3 Trial in Q1 of 2021, With an Interim Analysis Expected a Year Later.
Aravive Inc - Phase 3 Trial is Expected to Enroll About 300-400 Patients With High-grade Serous Ovarian Cancer.